GCN2 inhibition reduces mutant SOD1 clustering and toxicity and delays disease progression in an amyotrophic lateral sclerosis mouse model

• Didio Alberto Ortiz,
• Nuria Peregrín,
• Miguel Valencia,
• Rodrigo Vinueza-Gavilanes,
• Elisa Marín-Ordovas,
• Roberto Ferrero,
• María Jesús Nicolás,
• Gloria González-Aseguinolaza,
• Montserrat Arrasate,
• Tomás Aragón

Affiliations

Didio Alberto Ortiz

DNA and RNA Medicine Program, Center for Applied Medical Research (CIMA), University of Navarra

Nuria Peregrín

DNA and RNA Medicine Program, Center for Applied Medical Research (CIMA), University of Navarra

Miguel Valencia

Biomedical Engineering Program, Center for Applied Medical Research (CIMA), University of Navarra

Rodrigo Vinueza-Gavilanes

DNA and RNA Medicine Program, Center for Applied Medical Research (CIMA), University of Navarra

Elisa Marín-Ordovas

Neuroimmunology Department, Multiple Sclerosis Center of Catalonia (Cemcat), Vall d’Hebron Research Institute (VHIR)

Roberto Ferrero

DNA and RNA Medicine Program, Center for Applied Medical Research (CIMA), University of Navarra

María Jesús Nicolás

Biomedical Engineering Program, Center for Applied Medical Research (CIMA), University of Navarra

Gloria González-Aseguinolaza

DNA and RNA Medicine Program, Center for Applied Medical Research (CIMA), University of Navarra

Montserrat Arrasate

DNA and RNA Medicine Program, Center for Applied Medical Research (CIMA), University of Navarra

Tomás Aragón

DNA and RNA Medicine Program, Center for Applied Medical Research (CIMA), University of Navarra